Last mentioned: 45m ago
Market Assessment
Analysts begin evaluating the long-term impact on Novartis's margins and the broader pharma supply chain.
Expansion Announcement
President Trump publicly states that Novartis will expand its U.S. manufacturing footprint due to tariffs.
Ministerial Warning
Health Minister José Ángel Portal Miranda warns of a looming humanitarian crisis in an AP interview.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
White House Meeting
CEO Vas Narasimhan meets with President Trump to discuss the pharmaceutical industry and trade.
Logistical Collapse
Ambulance services and medical supply flights begin widespread suspensions due to lack of fuel.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
U.S. Executive Order
President Trump signs order imposing tariffs on any nation providing oil to the Cuban government.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Venezuelan Oil Cutoff
U.S. announces end of Venezuelan oil shipments to Cuba following political shifts in Caracas.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
A severe energy crisis triggered by intensified U.S. sanctions and a fuel blockade has brought Cuba's healthcare infrastructure to a near-total standstill. With hospitals facing persistent power outages and ambulances grounded by fuel shortages, the island is facing an unprecedented humanitarian emergency.
President Donald Trump announced that Novartis AG will expand its U.S. manufacturing footprint following a White House meeting with CEO Vas Narasimhan. The administration attributes this shift to the impact of trade tariffs, signaling a potential trend of onshoring for major pharmaceutical players.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.